SRR1331335
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.378
- SPERMATOGENESIS+0.312
- PANCREAS_BETA_CELLS+0.307
- HEDGEHOG_SIGNALING+0.259
- MYOGENESIS+0.257
- BILE_ACID_METABOLISM+0.158
- UV_RESPONSE_DN+0.131
- ESTROGEN_RESPONSE_EARLY+0.114
- OXIDATIVE_PHOSPHORYLATION+0.082
- FATTY_ACID_METABOLISM+0.069
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.598
- MYC_TARGETS_V1-0.546
- INTERFERON_GAMMA_RESPONSE-0.529
- TNFA_SIGNALING_VIA_NFKB-0.476
- IL6_JAK_STAT3_SIGNALING-0.454
- E2F_TARGETS-0.446
- TGF_BETA_SIGNALING-0.437
- ALLOGRAFT_REJECTION-0.412
- G2M_CHECKPOINT-0.402
- INFLAMMATORY_RESPONSE-0.402
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1474951 | GTEX | — | 0.971 |
| 2 | SRR1310008 | GTEX | — | 0.969 |
| 3 | SRR1466993 | GTEX | — | 0.968 |
| 4 | SRR1332796 | GTEX | — | 0.968 |
| 5 | SRR1470703 | GTEX | — | 0.963 |
| 6 | SRR1334564 | GTEX | — | 0.962 |
| 7 | SRR1354734 | GTEX | — | 0.962 |
| 8 | SRR1480988 | GTEX | — | 0.960 |
| 9 | SRR1399028 | GTEX | — | 0.960 |
| 10 | SRR1350456 | GTEX | — | 0.959 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.378 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.312 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.307 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.259 | Inavolisib | — uncovered |
| MYOGENESIS | 0.257 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.158 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.131 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.114 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.082 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.069 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.060 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.049 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.049 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.044 | Inavolisib | — uncovered |